Avian AAV Vectors Overcoming Primate Antibody Barriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors, particularly those of primate origin, face limitations in transduction efficiency and immunological compatibility due to pre-existing antibodies in humans and restricted tissue tropism, necessitating the development of alternative vectors with distinct properties for effective gene therapy and gene transfer applications.
Innovation Solution
The use of avian adeno-associated virus (AAAV) vectors, which exhibit unique genetic and physical characteristics, including a universal inverted terminal repeat (ITR) capable of replication by both AAV2 and AAV5 Rep proteins, allowing for efficient transduction and overcoming immunological barriers, is proposed. These vectors are designed to carry nucleic acids between AAAV ITRs and include recombinant AAAV particles and proteins for targeted gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primate AAV vectors are used for gene delivery, then transduction efficiency is limited by pre-existing antibodies in humans, but using alternative vectors may overcome this immunological barrier
Solution Approach 1:
The patent changes the serological type parameter from primate AAV (AAV1-8) to avian AAV (AAAV), which is serologically distinct and not recognized by human pre-existing antibodies. This parameter change allows the vector to overcome immunological barriers while maintaining transduction capability in human cells
Solution Approach 2:
The AAAV vector system demonstrates universality by being able to replicate in both avian and mammalian cells, and its ITR can function with both AAV2 and AAV5 Rep proteins. This multi-functionality allows the vector to overcome species-specific immunological barriers while maintaining broad applicability
2Adaptability or versatility
If primate AAV vectors are used, then tissue tropism is restricted to certain cell types, but alternative vectors may expand tissue targeting capability
Solution Approach 1:
The patent changes the tissue tropism parameter by using AAAV capsid proteins which exhibit different cellular recognition patterns compared to primate AAV. This allows the vector to access cell types that are resistant to primate AAV while maintaining efficient transduction through the conserved Rep-ITR transcriptional machinery
3Adaptability or versatility
If AAAV vectors with universal ITR are used, then replication compatibility with both AAV2 and AAV5 Rep proteins is achieved, but vector design complexity increases
Solution Approach 1:
The AAAV ITR sequence is designed to be universal and can function with both AAV2 Rep proteins and AAV5 Rep proteins for replication and transcription. This universality simplifies the overall vector system by allowing flexibility in choosing helper plasmids or co-infection strategies without requiring multiple different ITR sequences
Solution Approach 2:
The vector design separates the ITR function from the capsid function, allowing the universal AAAV ITR to work with different Rep proteins while the capsid determines tissue tropism. This segmentation allows independent optimization of replication compatibility and tissue targeting
Data Source
AI summary
The present invention provides an Avian adeno-associated virus (AAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.